» Articles » PMID: 36577532

EUS-guided Celiac Plexus Neurolysis for Pancreas Cancer - Finally Established or Still Under Review?

Overview
Publisher Elsevier
Specialty Gastroenterology
Date 2022 Dec 28
PMID 36577532
Authors
Affiliations
Soon will be listed here.
Abstract

Patients with pancreas cancer must deal frequently with intractable and refractory pain. Endoscopic ultrasound guided-celiac plexus neurolysis (EUS-CPN) has been the most studied and used therapeutic technique aimed to destroy the pain fibres that allow the pancreas to communicate with the central nervous system. A neurolytic agent, most commonly ethanol, is optimally spread around the celiac axis in order to reduce pain and mitigate narcotic requirements. This can be performed early to prevent the spiral of pain and medication use, or more historically as salvage therapy. Different techniques to best administer the ethanol for effective EUS-CPN are still being debated. New EUS-guided injection techniques with radiofrequency, radioactive, and/or chemotherapeutic agents need more study.

Citing Articles

Endoscopic Ultrasound-Guided Treatments for Pancreatic Cancer: Understanding How Endoscopic Ultrasound Has Revolutionized Management of Pancreatic Cancer.

Singh S, Facciorusso A, Vinayek R, Dutta S, Dahiya D, Aswath G Cancers (Basel). 2025; 17(1.

PMID: 39796719 PMC: 11719510. DOI: 10.3390/cancers17010089.


Mechanism of LDH and IL-8 involved in pancreatic cancer pain and the correlation of pain degree.

Zhou Z, Guo Z, Lu X, Xu X J Med Biochem. 2024; 43(5):664-670.

PMID: 39712504 PMC: 11662958. DOI: 10.5937/jomb0-48160.